Bioprocess Technology Market Report 2026

The bioprocess technology market size has grown rapidly in recent years. It will grow from $28.71 billion in 2025 to $33.16 billion in 2026 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to expansion of biopharmaceutical manufacturing, increasing use of cell-based therapies, growth of research and development activities, rising demand for biologics, availability of advanced laboratory infrastructure.

The bioprocess technology market size is expected to see rapid growth in the next few years. It will grow to $59.03 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to increasing investments in biologics and biosimilars, rising adoption of continuous bioprocessing, expansion of personalized medicine production, growing focus on sustainable biomanufacturing, increasing integration of digital process control systems. Major trends in the forecast period include increasing adoption of single-use bioprocessing systems, rising demand for scalable cell culture technologies, growing integration of automation in bioreactors, expansion of advanced cell line development techniques, enhanced focus on process optimization and yield efficiency.

The rising prevalence of chronic diseases is anticipated to further fuel the growth of the bioprocess technology market. Chronic diseases, lasting three months or more and potentially worsening over time, are a significant focus for bioprocess technology. The technology contributes to the development and production of gene therapies, vaccines, cell culture and fermentation, and monoclonal antibody production aimed at addressing chronic diseases, thereby advancing medicine and enhancing the quality of life for individuals. According to the National Library of Medicine, the number of people in the U.S. aged 50 and older with at least one chronic condition is projected to increase by 99.5% to 142.66 million by 2050. Additionally, the World Health Organization (WHO) reported in September 2022 that 74% of all deaths globally are caused by noncommunicable diseases (NCDs) or chronic diseases, amounting to 41 million deaths annually. The increasing prevalence of chronic diseases is a significant driver for the growth of the bioprocess technology market.

Major companies operating in the bioprocess technology market are innovating services options, such as the custom organoid line expansion service, to gain a competitive edge in the market. The custom organoid line expansion service is a service that uses proprietary bioreactor and bioprocess technology to scale up the production of organoids. For instance, in July 2023, Molecular Devices LLC, a US-based Research and development company launched custom organoid line expansion service. The custom organoid line expansion service helps researchers to screen thousands to tens of thousands of drug candidates in parallel on organoids from the same source. It is designed to support next-generation drug discovery research and enables the development of more efficient, reproducible, and scalable patient-derived organoids (PDOs).

In September 2023, Repligen Corporation, a US-based company focused on developing and producing materials for the manufacture of biological drugs, acquired Metenova Corporation for an undisclosed amount. This acquisition aims to expand Repligen Corporation's product offerings and enhance its position in the bioprocess market. Metenova, based in Sweden, is an innovator and manufacturer of bottom-mounted magnetic mixers designed for use in the pharmaceutical and biotechnology sectors.

Major companies operating in the bioprocess technology market are Sartorius AG; Thermo Fisher Scientific Inc.; Lonza Group AG; F. Hoffmann-La Roche Ltd.; Becton Dickinson and Company; Merck KGa; GE Healthcare; Eppendorf AG; Bio-Rad Laboratories; Catalent Inc.; Advanced Instruments LLC; MilliporeSigma; Repligen Corporation; Danaher Corporation; PerkinElmer Inc.; Applikon Biotechnology; New Brunswick Scientific Co. Inc.; Avid Bioservices; Meissner Filtration Products; 3M; Eppendorf Biochip Systems; Fermenter Bioreactor; Solaris Biotechnology Srl; Aber Instruments; Cytiva.

North America was the largest region in the bioprocess technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the bioprocess technology market report during the forecast period. The regions covered in the bioprocess technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprocess technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bioprocess technology market by increasing costs of imported bioreactors, filtration systems, sensors, automation equipment, and specialized laboratory components used in cell culture and biomanufacturing. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on imported high-precision equipment, while Asia-Pacific faces higher capital costs for scaling production facilities. These tariffs are increasing setup costs and extending project timelines. However, they are also encouraging local manufacturing of bioprocess equipment, regional supplier development, and increased investment in domestic biomanufacturing capabilities.

The bioprocess technology market research report is one of a series of new reports that provides bioprocess technology market statistics, including bioprocess technology industry global market size, regional shares, competitors with a bioprocess technology market share, detailed bioprocess technology market segments, market trends and opportunities, and any further data you may need to thrive in the bioprocess technology industry. This bioprocess technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bioprocessing technology involves the creation of biological products such as medications, chemicals, and biofuels through living organisms such as bacteria, yeast, and cells. This technology is instrumental in producing pharmaceuticals, nutritional supplements, flavors, fuels, and chemicals, utilizing biocatalysts such as enzymes or microorganisms within a bioreactor.

The primary categories of bioprocess technologies include cell culture, cell expansion, flow cytometry, cell line development, and virus infiltration. Cell culture denotes the controlled growth and preservation of cells in a laboratory setting, often utilizing bioprocessing techniques to manufacture biologics at scale for research, clinical investigations, and commercial applications. These technologies find diverse applications in biopharmaceuticals, specialty products, industrial chemicals, and environmental management, and cater to a range of end-users such as hospitals, research laboratories, and medical institutions.

The bioprocess technology market consists of revenues earned by entities by providing biologics safety testing, and tangential flow filtration. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprocess technology market also includes sales of instruments, consumables, and accessories that include bioprocess analyzers, osmometers, incubators, and bioreactors used in bioprocessing technology services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.